Physician profile
Maged D Farid
NPI 1780758771
$3,341.23
in general payments reported to CMS, 2019-2025
22 companies · $338 in 2025
The $338 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $157 · 2021: $385 · 2022: $486 · 2023: $1,053 · 2024: $636 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $641.83 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Corium, LLC | $564.70 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $374.56 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $224.48 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $200.73 | 2025 | Jornay Pm |
| Tris Pharma INC | $191.45 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $184.12 | 2021-2024 | |
| Neurelis, INC. | $177.08 | 2023 | Valtoco |
| Sanofi Pasteur INC. | $167.93 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $126.29 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Atricure, INC. | $86.78 | 2024 | |
| Cranial Technologies, INC | $67.97 | 2020-2023 | Doc Band |
| Shire North American Group INC | $63.54 | 2019 | |
| Phadia US INC. | $60.07 | 2022-2024 | Immunocap |
| Pfizer INC. | $58.27 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $39.04 | 2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $29.17 | 2025 | |
| Alk-Abello, INC | $28.09 | 2024 | Grastek, Ragwitek, Odactra |
| Rhodes Pharmaceuticals L.P. | $14.25 | 2019 | |
| Seqirus USA INC | $14.02 | 2020 | |
| Cipher Pharmaceuticals US LLC | $13.62 | 2025 | Natroba, Spinosad |
| Vertical Pharmaceuticals, LLC | $13.24 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Farid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.